Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Thrombolytic therapy: future issues

M M Samama1, J Acar

  • 1Service d'Hématologie Biologique, Paris, France.

Thrombosis and Haemostasis
|July 1, 1995
PubMed
Summary
This summary is machine-generated.

Thrombolytic therapy improves survival in acute myocardial infarction but faces challenges like insufficient lysis and bleeding. Research focuses on earlier treatment, better drug combinations, and improved monitoring to enhance outcomes.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

In vitro activity of secnidazole against Atopobium vaginae, an anaerobic pathogen involved in bacterial vaginosis.

Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases·2009
Same author

Antibiotic resistance in nosocomial pulmonary pathogens.

Seminars in respiratory and critical care medicine·2005
Same author

Fumaric acid in apple juice: a potential indicator of microbial spoilage of apples used as raw material.

Food additives and contaminants·2004
Same author

Antimicrobial resistance: an overview.

Revue scientifique et technique (International Office of Epizootics)·2001
Same author

Antimicrobial resistance: risk analysis methodology for the potential impact on public health of antimicrobial resistant bacteria of animal origin.

Revue scientifique et technique (International Office of Epizootics)·2001
Same author

Antimicrobial resistance: responsible and prudent use of antimicrobial agents in veterinary medicine.

Revue scientifique et technique (International Office of Epizootics)·2001
Same journal

Anti-TFPI Single-Domain Antibodies: Novel Rebalancing Therapies for Hemophilia and Other Rare Bleeding Disorders.

Thrombosis and haemostasis·2026
Same journal

The Interaction of Fibrin with Endothelial Cell Receptor N-Cadherin Promotes Fibrin-Dependent Angiogenesis.

Thrombosis and haemostasis·2026
Same journal

Antiphospholipid Antibodies and Atrial Fibrillation: Clinical Implications and the TaPL AF Study Design.

Thrombosis and haemostasis·2026
Same journal

Prasugrel vs. Ticagrelor: Can TUXEDO-2 Settle the Debate?

Thrombosis and haemostasis·2026
Same journal

Methylglyoxal Promotes RBC-Driven Procoagulant Activity and Venous Thrombosis under Diabetes-Relevant Conditions.

Thrombosis and haemostasis·2026
Same journal

Management of Inferior Vena Cava Thrombosis: Guidance from the Italian Society for the Study of Haemostasis and Thrombosis.

Thrombosis and haemostasis·2026
See all related articles

Area of Science:

  • Cardiology
  • Thrombosis
  • Emergency Medicine

Background:

  • Thrombolytic therapy is a key treatment for acute myocardial infarction (MI), significantly reducing hospital mortality by 30-40%.
  • Current challenges include insufficient thrombolysis in 25% of patients, reocclusion rates of 6-16%, and a 0.5% risk of intracranial hemorrhage.
  • Potential improvements involve earlier medical intervention, more effective thrombolytic and antithrombotic agents, and safer drug combinations with enhanced laboratory monitoring.

Purpose of the Study:

  • To review the current status and challenges of thrombolytic therapy in acute myocardial infarction (MI).
  • To explore potential improvements in thrombolytic therapy for MI.
  • To discuss the evolving role of thrombolysis in acute pulmonary embolism (PE) and acute ischemic stroke.

Main Methods:

Related Experiment Videos

  • Review of existing literature and megatrials on thrombolytic therapy.
  • Analysis of efficacy, safety concerns, and proposed improvements for thrombolysis in MI.
  • Evaluation of current evidence for thrombolysis in PE and stroke.

Main Results:

  • Thrombolysis significantly reduces mortality in acute MI but is limited by efficacy and safety concerns.
  • Improved outcomes in MI may be achieved through earlier treatment, combination therapies, and better monitoring.
  • Thrombolysis for PE shows potential but lacks mortality reduction data; its use in stroke is still experimental.

Conclusions:

  • Optimizing thrombolytic therapy for acute MI requires addressing lysis failure, reocclusion, and bleeding risks.
  • Further research is needed to establish the mortality benefits of thrombolysis in PE.
  • Thrombolysis for acute ischemic stroke holds promise but requires extensive clinical trials to define its benefit-risk ratio.